Multiple Sclerosis Market Size, Share & Trends Analysis Report By Drug Type (Immunomodulatory, Immunosuppressant, Interferons, Corticosteroids), By Route of Administration (Oral, Parenteral) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Multiple Sclerosis Market Size & Insights

The global multiple sclerosis market size was valued at USD 29.33 billion in 2025 and is projected to grow from USD 30.42 billion in 2026 to USD 40.67 billion by 2034, registering a CAGR of 3.7% during the forecast period from 2026 to 2034. North America dominated the multiple sclerosis market with a market share of 42.5% in 2025.

The growing prevalence of multiple sclerosis worldwide and rising awareness of this disease created by several governmental and non-governmental organizations are expected to drive the global multiple sclerosis market growth. Moreover, there has been a rise in the research and development of drugs and efficient treatments for multiple sclerosis, which is anticipated to create opportunities for market growth. This has led to developing novel and innovative treatments, further boosting the market expansion.

Segmental Analysis

The global multiple sclerosis market is bifurcated into drug type and route of administration.

By Drug Type

The global market for multiple sclerosis is segmented into immunomodulators, immunosuppressants, interferons, and corticosteroids.

The immunosuppressants segment owns the highest market share. The segment dominated the multiple sclerosis industry due to its great efficacy in treating patients with RRMS. The increasing approvals of medicines for treating Multiple Sclerosis strengthen the segment's expansion. The medications offer several additional benefits, including efficient administration at low doses, little side effects, and high effectiveness, contributing to the market's growth.

Alemtuzumab, fingolimod, natalizumab, interferon-beta preparations, glatiramer acetate, dimethyl fumarate, ocrelizumab, and teriflunomide are among the immunosuppressants that have been licensed for the treatment of relapsing forms of Multiple Sclerosis. Moreover, the segment of immunosuppressants is projected to experience the most rapid expansion, driven mainly by the emergence of innovative medications like Ocrevus and Lemtrada that specifically target the B cells and T cells implicated in the development of multiple sclerosis.

Request Customizationto receive a tailored report.

By Route of Administration

The global market for multiple sclerosis is bifurcated into oral and parenteral.

The oral segment dominates the global market. Due to patients' and physicians' preference for oral medications over injectable drugs, the oral category is projected to have the highest market share. Oral drugs are the preferred choice for the majority of individuals with multiple sclerosis who seek treatment for chronic and progressive neurological conditions, as per findings from Rutgers researchers. This can be attributed to various factors, including convenience, customer incentives, and endorsement by health insurance providers.

Moreover, the market expansion is strengthened by significant clinical advancements in orally administered drugs licensed for Multiple Sclerosis therapy, including fingolimod, teriflunomide, and dimethyl fumarate. The segment growth is driven by the launch of new oral medications such as Ozanimod, Laquinimod, Tecfidera, and Siponimod (BAF312).

Speak to an Analystto discuss market opportunities.

Regional Insights

Based on region, the global multiple sclerosis market share is bifurcated into North America, Europe, Asia-Pacific, Central and South America, and the Middle East and Africa.

North America Dominates the Global Market

North America is the most significant global market shareholder and is expected to expand substantially over the forecast period. The North American region is projected to have the highest market share globally due to its high incidence of Multiple Sclerosis, sophisticated healthcare facilities, access to innovative medications, increased investment in research and development, and advantageous reimbursement policies. As per the National Multiple Sclerosis Society, Canada has the highest occurrence rate of Multiple Sclerosis globally, with a prevalence of 291 cases per 100,000 people. Likewise, according to the National MS Society, around 1 million individuals in the United States are afflicted with multiple sclerosis. Businesses such as Sanofi SA, Novartis AG, and Biogen have established a solid presence in the US market and are consistently concentrating more on developing novel therapies.

For instance, in August 2023, the FDA approved Sandoz's natalizumab-sztn (Tyruko) injection treatment as the first biosimilar for multiple sclerosis (MS) in the United States. Furthermore, in January 2024, the Kessler Foundation's research team was awarded a grant of USD 39,994 by the Consortium of Multiple Sclerosis Centers. The grant aims to study the potential cognitive benefits of combining aerobic cycling with virtual reality in individuals diagnosed with multiple sclerosis (MS). The study will primarily examine processing speed, which refers to the duration it takes for an individual to absorb, comprehend, and react to information. This cognitive function is frequently compromised in individuals with multiple sclerosis (MS). Moreover, research has demonstrated that reduced processing speed adversely affects the overall quality of life in individuals with Multiple Sclerosis. Hence, substantial funding from governmental and non-governmental entities propels the market expansion.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia-Pacific: Fastest Growing Region

Asia-Pacific is expected to experience the highest growth rate in the global market. This is due to a significant and unexplored patient population, the development of better healthcare infrastructure, rising disposable income, and increased government efforts to assist the Multiple Sclerosis community in the region. Moreover, various organizations have increased research spending in this area, which accelerates the development and testing of multiple sclerosis medications and treatments. For instance, with an initial investment of USD 4 million, the inaugural adaptive clinical study for Australians suffering from Multiple Sclerosis aims to cure neurological damage caused by progressive multiple sclerosis.

The experiment, scheduled to begin in January 2024, will allow researchers to simultaneously examine the possible advantages of many drugs. This offers hope to those suffering from one of the most severe types of multiple sclerosis, who now have very few treatment choices available to them. The PLATYPUS trial, a multi-arm, multi-stage (MAMS) adaptive and innovative design, will evaluate the efficacy of two repurposed drugs in multiple sclerosis. This trial seeks to deliver timely and definitive results regarding treatment effectiveness by collaborating with clinicians and researchers from national and international backgrounds. These factors contribute to the regional multiple sclerosis industry growth.

List of Key and Emerging Players in Multiple Sclerosis Market